New Experimental Compound 10 Shows Promise in Slowing Alzheimer's Progression
Ursula Quitterer, a Professor of Molecular Pharmacology at ETH Zurich, has introduced an experimental treatment called Compound 10, which has shown potential in slowing the progression of Alzheimer's disease in preclinical studies involving mice. The research, which has been ongoing for nearly two decades, began with brain tissue samples from dementia patients obtained during tumor surgeries at Ain Shams University Hospital in Cairo. These samples allowed Quitterer and her team to investigate the role of the enzyme GRK2 in dementia.
GRK2 is crucial for cellular responses to various signals and stressors, playing a significant role in both the heart and brain. The researchers discovered that in brain tissue from dementia patients, there was a notable increase in the inactive form of GRK2. This inactive enzyme tends to aggregate within brain cells, particularly in models of Alzheimer's disease, leading to mitochondrial dysfunction and increased production of amyloid beta, a protein fragment linked to Alzheimer's.
The presence of inactive GRK2 creates a detrimental cycle: as amyloid beta accumulates, it exacerbates stress on nerve cells, which in turn leads to more inactive GRK2 and further aggregation. To break this cycle, Quitterer’s team developed several compounds, with Compound 10 emerging as particularly effective. It prevents the aggregation of GRK2, thereby enhancing mitochondrial function and reducing amyloid beta levels in cells, which helps protect nerve cells from death.
Interestingly, the benefits of Compound 10 extend beyond the brain. In mouse models, it also positively impacted heart function and appeared to slow some signs of aging, such as the development of grey hair. Despite these promising results, it is important to note that these findings are still in the preclinical stage, and Compound 10 has yet to be developed into a treatment for humans.
The lengthy timeline of Alzheimer's research, which often requires studies involving older animals and extensive experimentation, has contributed to the slow progress in developing new treatments. Quitterer emphasizes the importance of identifying new targets like GRK2, as current Alzheimer's medications primarily offer limited benefits by delaying disease progression rather than providing a cure. The hope is that Compound 10 could complement existing treatments, potentially improving the quality of life for those affected by Alzheimer's disease. The research team is currently seeking partnerships to advance the development of Compound 10.




